Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib

Abstract

A phase 2 biomarker-driven study using epidermal growth factor receptor 1 FGFR1 gene copy number by silver in-situ hybridization (SISH) and messenger RNA expression by in-situ hybridization (ISH) in lung cancer patients treated with ponatinib was conducted. FGFR1 ISH and SISH positivity may be associated with a distinct phenotype. Ponatinib's poor tolerance limited the number of patients treated on study.